Demographic and clinical characteristics of patients with systemic lupus erythematosus (SLE) and a haematological malignancy (HM)*
| All patients | HM after SLE | HM before/concurrent | |||||
|---|---|---|---|---|---|---|---|
| n | 45‡ | 29 | 16 | p Value† | |||
| Age | |||||||
| at SLE | 39±15.5 | 35.8±15.3 | 44.7±14.4 | 0.06 | |||
| at HM | 47.8±13.2 | 51.8±9.8 | 40.5±15.6 | 0.005 | |||
| Race | |||||||
| White | 38 | (84%) | 25 | (86%) | 13 | (81%) | NS |
| Black | 6 | (13%) | 3 | (10%) | 3 | (19%) | NS |
| Other | 1 | (2%) | 1 | (3%) | 0 | (0%) | NS |
| Gender | |||||||
| Female | 38 | (84%) | 27 | (93%) | 11 | (69%) | 0.079 |
| Male | 7 | (16%) | 2 | (7%) | 5 | (31%) | NS |
| Clinical | |||||||
| Malar rash | 13 | (29%) | 9 | (31%) | 4 | (25%) | NS |
| Discoid rash | 3 | (7%) | 2 | (7%) | 1 | (6%) | NS |
| Photosensitivity | 18 | (40%) | 12 | (41%) | 6 | (38%) | NS |
| Oral ulcers | 16 | (36%) | 13 | (45%) | 3 | (19%) | NS |
| Arthritis | 39 | (87%) | 27 | (93%) | 12 | (75%) | NS |
| Serositis | 14 | (31%) | 10 | (34%) | 4 | (25%) | NS |
| Renal | 10 | (22%) | 7 | (24%) | 3 | (19%) | NS |
| Neurological | 5 | (11%) | 3 | (10%) | 2 | (13%) | NS |
| Haematological | 38 | (84%) | 27 | (93%) | 11 | (69%) | 0.079 |
| ANA | 41/43 | (95%) | 25/27 | (93%) | 16 | (100%) | NS |
| dsDNA Ab | 24/41 | (59%) | 16/25 | (64%) | 8 | (50%) | NS |
| Smith Ab | 2/35 | (6%) | 2/19 | (10%) | 0 | (0%) | 0.006 |
| Phospholipid Ab | 21/40 | (52%) | 16/24 | (67%) | 5 | (31%) | 0.021 |
| Prednisone | 34 | (76%) | 24 | (83%) | 10 | (63%) | NS |
| Antimalarial | 33 | (73%) | 22 | (76%) | 11 | (69%) | NS |
| Immunosuppression | 21/44 | (47%) | 15/28 | (54%) | 6 | (37%) | NS |
| Cyclophosphamide | 10/44 | (23%) | 8/28 | (29%) | 2 | (13%) | NS |
| Azathioprine | 8/44 | (18%) | 5/28 | (18%) | 3 | (19%) | NS |
| Methotrexate | 10/44 | (23%) | 8/28 | (29%) | 2 | (13%) | NS |
| Mycophenolate | 9/44 | (20%) | 8/28 | (29%) | 1 | (6%) | NS |
*Clinical features defined by ACR criteria for SLE when applicable.
†Comparing the HM-after-SLE group with the HM-before/concurrent-SLE group.
‡Denominator=full sample unless otherwise indicated.
Ab, antibody; ACR, American College of Rheumatology; ANA, antinuclear antibody; dsDNA, double-stranded DNA; NS, not significant.